| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328636 | Critical Reviews in Oncology/Hematology | 2015 | 8 Pages |
•There were indications of PAX3–FOXO1 being an unfavorable prognostic factor.•No survival difference between positive and negative PAX3/7–FOXO1 fusion gene.•This hypothesis requires testing by means of randomized clinical trials.
PurposeThe objective of this systematic review is to provide an unprecedented summary of the prognostic impact of PAX3/7–FOXO1 fusion status in alveolar rhabdomyosarcoma.MethodsStudies evaluating PAX3/7–FOXO1 fusion gene or its variants as a prognostic marker were systematically searched and comparative meta-analysis of overall survival was carried out.ResultsA total of 7 studies comprising 993 patients with rhabdomyosarcoma were included. Three eligible studies showed no significant difference of survival between fusion positive and negative alveolar rhabdomyosarcoma. Four eligible studies showed that PAX3–FOXO1 fusion variant may indicate a lower survival probability than PAX7–FOXO1, although the effect did not reach a level of statistical significance (pooled hazard ratios, 1.66; 95% CI, 0.95–2.89; p = 0.07).ConclusionsThere was no significant difference in the overall survival between patients with the positive and negative fusion gene, but there were indications of PAX3–FOXO1 being an unfavorable prognostic factor.
